- Last Close 115.46
- Sector Healthcare
- Industry Drug Manufacturers - Specialty & Generic
- Investment Style Mid Growth
- Day Range 114.81 – 115.97
- Year Range 89.04 – 129.29
- Market Cap 11.2750 Bil
- Volume / Avg 542,268.0 / 712,154.4
- Price / Sales 6.99
- Price / Book 6.08
- Forward Div Yield —
- Trailing Div Yield —
Morningstar‘s Stock Analysis NBIX
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile NBIX
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
San Diego, CA, 92130
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of NBIX’s competitive advantage.
|+$0.80 (0.70%)||−$1.10 (1.07%)||—|
|11.27 Bil||127.47 Bil||—|
|Drug Manufacturers - Specialty & Generic||Drug Manufacturers - General||Drug Manufacturers - Specialty & Generic|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Neurocrine Biosciences Inc Stock
No. NBIX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
NBIX’s market cap is 11.27 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
NBIX’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
NBIX’s price/sales is 6.99.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.
NBIX’s price/forward earnings is 65.23.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.
NBIX’s price/book is 6.08.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See NBIX’s valuation ratios compared to the Market Index.
NBIX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare NBIX’s historical performance against its industry peers and the overall market.